ALSO NOTED: Nexavar OK'd for use against liver cancer; Japan's Olympus to buy Gyrus in $1.9 billion deal;

> Bayer and Onyx Pharmaceuticals got the FDA's nod to market Nexavar to treat liver cancer; the drug already is used against kidney cancer. Report [1]

> Surgical equipment maker Gyrus recommended that its shareholders accept a $1.9 billion cash tender offer from Olympus, the Japanese camera company. Report [2]

> Schering-Plough has wrapped up its acquisition of Organon BioSciences. Report [3]

> Sales of over-the-counter cold meds for kids have fallen sharply since an FDA panel concluded they shouldn't be used in children younger than 6. Report [4]

> India's Plethico Pharma is buying U.S.-based Natrol, a manufacturer and marketer of nutritional products, for $80.7 million. Report [5]

> A Dallas whistleblower has implicated a multitude of surgical suppliers in a Medicare-fraud suit just unsealed in federal court. Report [6]

And Finally... The much talked-about Baby Boomer generation is heading into their 50s--and they're looking to biotechnology to not only to extend their lives, but to make their later years better. Report [7]